

# CITATION REPORT

List of articles citing

Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis

DOI: 10.1111/bcp.13150

British Journal of Clinical Pharmacology, 2017, 83, 642-652.

**Source:** <https://exaly.com/paper-pdf/67736704/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
38	High adherence to the <b>Wise List</b> treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. <i>BMJ Open</i> , <b>2017</b> , 7, e014345	3	59
37	Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 1417-1425	2.8	50
36	Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1133-1138	3	22
35	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 1315-1322	2.8	14
34	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 642-652	3.8	37
33	Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. <i>Annals of Translational Medicine</i> , <b>2017</b> , 5, 322	3.2	42
32	The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 663-670	2.8	13
31	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , <b>2018</b> , 49, 2122-2128	6.7	36
30	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , <b>2018</b> , 39, 3973-3979	9.5	79
29	Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1653-1662	2.8	3
28	Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 65, 489-517	4.3	10
27	Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e163	4.7	19
26	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 907-920	5.8	107
25	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2524-2539	3.8	29
24	Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012646	6	15
23	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221500	3.7	9
22	Venous thromboembolism 2011-2018 in Stockholm: a demographic study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 668-673	5.1	7

21	Secondary prevention after stroke/transient ischemic attack: A randomized audit and feedback trial. <i>Acta Neurologica Scandinavica</i> , <b>2019</b> , 140, 107-115	3.8	5
20	Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 867-878	2.6	3
19	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , <b>2019</b> , 213, 35-46	4.9	28
18	Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000-2016: A Drug Utilization Study. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 150-160	5.8	10
17	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 287-294	6.1	4
16	Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 73, 1013-1021	4.3	4
15	Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001-2016. <i>Scientific Reports</i> , <b>2020</b> , 10, 12468	4.9	3
14	Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 925-934	3.8	4
13	Printed educational materials: effects on professional practice and healthcare outcomes. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD004398	5.2	16
12	Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1288-1297	4.9	0
11	Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 867-876	2.8	11
10	Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 27, 100505	2.4	3
9	Uninterrupted Oral Anticoagulant Therapy in Patients Undergoing Unplanned Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 754-763	5	4
8	Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 3597-3604	4	2
7	Pharmacoepidemiology. <b>2020</b> , 415-432		
6	Decrease in blood donation rates in Japan: a time series analysis. <i>Revista Brasileira De Epidemiologia</i> , <b>2020</b> , 23, e200047	1.3	
5	Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 682890	5.6	0
4	The Impact of the Social Distancing Policy on COVID-19 Incidence Cases and Deaths in Iran from February 2020 to January 2021: Insights from an Interrupted Time Series Analysis. <i>Yale Journal of Biology and Medicine</i> , <b>2021</b> , 94, 13-21	2.4	7

- 3 The effect of COVID-19 on public hospital revenues in Iran: An interrupted time-series analysis.. *PLoS ONE*, **2022**, 17, e0266343 3-7
- 2 Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. **2022**, 06, e238-e247 ○
- 1 Time trends in atrial fibrillation-related stroke during 2001-2020 in Sweden: a nationwide, observational study. **2023**, 100596 ○